GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (TSX:MBX) » Definitions » EV-to-EBIT

Microbix Biosystems (TSX:MBX) EV-to-EBIT : 7.89 (As of Jun. 13, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Microbix Biosystems EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Microbix Biosystems's Enterprise Value is C$39.19 Mil. Microbix Biosystems's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was C$4.97 Mil. Therefore, Microbix Biosystems's EV-to-EBIT for today is 7.89.

The historical rank and industry rank for Microbix Biosystems's EV-to-EBIT or its related term are showing as below:

TSX:MBX' s EV-to-EBIT Range Over the Past 10 Years
Min: -962.03   Med: 12.95   Max: 1031.44
Current: 7.9

During the past 13 years, the highest EV-to-EBIT of Microbix Biosystems was 1031.44. The lowest was -962.03. And the median was 12.95.

TSX:MBX's EV-to-EBIT is ranked better than
53.65% of 425 companies
in the Biotechnology industry
Industry Median: 9.78 vs TSX:MBX: 7.90

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Microbix Biosystems's Enterprise Value for the quarter that ended in Mar. 2024 was C$44.00 Mil. Microbix Biosystems's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was C$4.97 Mil. Microbix Biosystems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 11.29%.


Microbix Biosystems EV-to-EBIT Historical Data

The historical data trend for Microbix Biosystems's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems EV-to-EBIT Chart

Microbix Biosystems Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.18 -9.54 15.99 23.48 45.97

Microbix Biosystems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -200.67 -28.83 45.97 10.28 8.86

Competitive Comparison of Microbix Biosystems's EV-to-EBIT

For the Biotechnology subindustry, Microbix Biosystems's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Microbix Biosystems's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Microbix Biosystems's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Microbix Biosystems's EV-to-EBIT falls into.



Microbix Biosystems EV-to-EBIT Calculation

Microbix Biosystems's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=39.190/4.966
=7.89

Microbix Biosystems's current Enterprise Value is C$39.19 Mil.
Microbix Biosystems's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$4.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microbix Biosystems  (TSX:MBX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Microbix Biosystems's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=4.966/43.999205
=11.29 %

Microbix Biosystems's Enterprise Value for the quarter that ended in Mar. 2024 was C$44.00 Mil.
Microbix Biosystems's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$4.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Microbix Biosystems EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Microbix Biosystems (TSX:MBX) Business Description

Traded in Other Exchanges
Address
265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3
Microbix Biosystems Inc develops biological products and technologies. The company manufactures and develops cell culture-based biological products and technologies. It has developed and acquired two technologies; Kinlytic and LumiSort. The company's operating segment includes Antigen, QAPs DxTM and Other Includes Kinlytic. It generates maximum revenue from the Antigen QAPs segment. Geographically, it derives a majority of revenue from North America.
Executives
James Stuart Currie Senior Officer

Microbix Biosystems (TSX:MBX) Headlines

No Headlines